Saturday 17 October 2026
Export LIPO’s income statement to Excel — free account
Lipella Pharmaceuticals Inc.
LIPO Healthcare Biotechnology
Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023. In the quarter to September 2025, revenue fell 36.4%, EPS grew 78.3% and free cash flow fell 41.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.00
NaN
Follow LIPO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Trend | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 23.20 | 6.80 | 2.21 |
Analyst estimates 2025–2027 Powerpack |
|||
| High | — | — | — | — | — | — | — | 61.76 | 48.80 | 12.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 5 | 7 | 7 | 7 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.05 | 0.03 | 0.06 | 0.08 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 1 | 1 | 0 | 0 | 0 | 1 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | 0 | 0 | (2) | (3) | (5) | (5) | |||||
| EBT margin, % | — | — | — | — | (8.90) | (6.42) | (719.44) | (1,410.26) | (1,027.36) | (935.18) | |||||
| Net income | — | — | — | — | 0 | 0 | (2) | (3) | (5) | (5) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.12 | 1.44 | 0.61 | 0.36 | 0.60 | 0.51 | ||||
| Earnings | — | — | — | — | (0.01) | (0.09) | (4.38) | (5.12) | (6.16) | (4.79) | |||||
| Cash flow | — | — | — | — | (0.01) | (0.04) | (2.32) | (3.61) | (4.20) | (3.77) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 | |||||
| Free cash flow | — | — | — | — | (0.01) | (0.04) | (2.32) | (3.61) | (4.22) | (3.77) | |||||
| Book value | — | — | — | — | (0.02) | 0.70 | 3.34 | 9.21 | 4.19 | 1.83 | |||||
| Shares, m | — | — | — | — | 6 | 1 | 0 | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 12.56 | 5.96 | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 2.78 | 1.80 | 1.67 | |||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 5.90 | 2.45 | |||||
| EV/FCF | — | — | — | — | (9.13) | (9.13) | (9.13) | (4.46) | (0.84) | (0.33) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | 0 | (1) | (2) | (3) | (4) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | — | |||||
| Free cash flow | — | — | — | — | 0 | 0 | (1) | (2) | (3) | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 0 | 1 | 5 | 3 | 2 | ||||
| Total debt | — | — | — | — | 0 | 0 | 0 | 0 | — | — | |||||
| Net debt | — | — | — | — | 0 | 0 | (2) | (5) | (3) | (2) | |||||
| Shareholders’ equity | — | — | — | — | 0 | 0 | 1 | 5 | 3 | 2 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (11.49) | (125.71) | (65.24) | (96.96) | (160.49) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | (35.80) | (197.76) | (85.18) | (118.13) | (198.12) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Jun 2025
Charts ten years each
Lipella Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ERNA Ernexa Therapeutics Inc. | $3.5M | — (loss-making) | — (loss-making) | −94.12% (below 0%: shrinking) | n/m | −64.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $3.5M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| CVKD Cadrenal Therapeutics, Inc. | $3.5M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IOBTQ IO Biotech, Inc. | $3.5M | — (loss-making) | — | — | n/m | +11.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| UNBX UNITY Biotechnology, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | −23.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.3M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.2M | — (loss-making) | — (loss-making) | −100.78% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $3.4M | — | — | — | — | −12.92% | 0.00% | 0.00% |
Lipella Pharmaceuticals Inc. (LIPO) key facts
- Strength: Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023.
- Lipella Pharmaceuticals Inc. (LIPO) is a Biotechnology company in the Healthcare sector.
- Return on equity was −198.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −10.72 (distress zone) for fiscal 2024.